Personalis v. Foresight Diagnostics: ctDNA Patent Dispute Ends in Dismissal
What would you like to do next?
Choose your path based on your current needs:
📋 Case Summary
| Case Name | Personalis, Inc. v. Foresight Diagnostics Inc. |
| Case Number | 1:23-cv-01623 (D. Colo.) |
| Court | U.S. District Court for the District of Colorado |
| Duration | June 26, 2023 – July 12, 2024 382 days |
| Outcome | Dismissed with Prejudice |
| Patents at Issue | |
| Accused Products | ctDNA and Liquid Biopsy Diagnostics |
Case Overview
The Parties
⚖️ Plaintiff
California-based precision medicine company specializing in advanced genomic sequencing and cancer immunogenomics.
🛡️ Defendant
Colorado-based molecular diagnostics company focused on ctDNA-based cancer detection.
Patents at Issue
This dispute centered on three U.S. patents relating to **methods and systems for genetic analysis**, specifically covering **methods for using mosaicism in nucleic acids sampled distal to their origin** — a technically sophisticated area in liquid biopsy diagnostics.
- • US 11,643,685 — Genetic analysis and mosaicism-based nucleic acid detection
- • US 11,584,968 — Methods and systems for genetic analysis
- • US 11,649,507 — Genetic analysis systems and methods
Developing a ctDNA diagnostic product?
Check if your genetic analysis methods might infringe these or related patents before launch.
The Verdict & Legal Analysis
Outcome
The case was **dismissed with prejudice** pursuant to Federal Rule of Civil Procedure 41, as stipulated jointly by both parties. Each party agreed to bear its own attorneys’ fees and costs. No damages award, injunctive relief, or royalty arrangement was publicly disclosed as part of the termination record. This dismissal acts as a final adjudication, preventing Personalis from refiling the same claims against Foresight on these patents for the same accused conduct.
Key Legal Issues
The action was classified as a standard patent infringement case. Because it resolved through stipulated dismissal rather than judicial ruling, no formal interpretation of the asserted patent claims was issued by the court. No infringement or validity findings are on the public record, meaning the legal strength of the asserted patents — as construed against the accused products — remains untested by judicial scrutiny. The mutual agreement that each party bears its own costs suggests a negotiated resolution rather than outright capitulation by either side, which is a common strategy in complex IP disputes like those in the liquid biopsy and genomic diagnostics market.
Freedom to Operate (FTO) Analysis
This case highlights critical IP risks in genomic diagnostics. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this litigation.
- View all related patents in the ctDNA technology space
- See which companies are most active in genomic diagnostics patents
- Understand claim construction patterns for mosaicism-based detection
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own genomic diagnostic technology.
- Input your product description or technical features
- AI identifies potentially blocking patents
- Get actionable risk assessment report
High Risk Area
Mosaicism-based nucleic acid detection
3 Patents at Issue
Covering key ctDNA analysis methods
Strategic Design-Arounds
Possible with deep IP analysis
✅ Key Takeaways
Stipulated Rule 41 dismissals with prejudice bar re-assertion of the same claims — confirm scope before filing.
Search related case law →Multi-patent assertion strategies covering related application families increase leverage in licensing negotiations.
Explore precedents →Monitor prosecution histories of US11643685, US11584968, and US11649507 for claim scope relevant to ctDNA and mosaicism-based diagnostics.
Track patent family changes →Symmetric fee allocation in dismissal suggests negotiated resolution — track any subsequent licensing activity between these parties.
View company IP strategies →Frequently Asked Questions
Three U.S. patents: US11643685B2, US11584968B2, and US11649507B2, covering methods for genetic analysis and mosaicism-based nucleic acid detection.
Both parties jointly stipulated to dismissal under Fed. R. Civ. P. 41, with each bearing its own costs. No court ruling on infringement or validity was issued.
It signals active enforcement of genomic diagnostics IP and underscores the importance of FTO analysis for companies developing liquid biopsy technologies.
Ready to Strengthen Your Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision.
References
- USPTO Patent Full-Text Database (Google Patents)
- PACER Case Lookup: 1:23-cv-01623
- U.S. District Court for the District of Colorado
- Cornell Legal Information Institute — 35 U.S.C. § 285
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.